Posts by Peter W. PENG

Healthy living for all, together we uphold, and start a new chapter! September is the National Healthy Lifestyle Promotion Month. We focus on breast cancer, a significant disease threatening women's health, and have specially invited authoritative experts in the field of breast cancer from China to discuss the scientific prevention and treatment of breast cancer and the importance of a healthy lifestyle. The experts unanimously emphasize that facing the disease scientifically, actively preventing it, and treating it precisely are the keys to overcoming breast cancer. Let us join hands with a scientific attitude and firm belief to protect the beauty and dignity of life, and promote breast cancer prevention and treatment to new heights, contributing to the great goal of a Healthy China! We hope that through the experts' interpretations, we can not only enhance the public's understanding of breast cancer but also encourage patients and their families to actively participate in screening and advocate a healthy lifestyle, jointly promoting the development of breast cancer treatment towards more individualized and precise directions. Let us work together to light the way for breast cancer patients and create a healthy and bright future!

From October 19th to 20th, 2024, the inaugural St.Gallen International Breast Cancer Conference (SGBCC) China Tour was successfully held in Nanjing. The St.Gallen International Breast Cancer Conference is the most influential international conference globally concerning the diagnosis and treatment of early-stage breast cancer. Professor Michael Gnant, the chairman of the St.Gallen Breast Cancer Consensus Meeting,

The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.

Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many of these studies have been led by Chinese researchers, contributing to original findings in the field. In this annual review, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University shares the key advancements in systemic therapy for TNBC, showcasing how precision medicine is gradually transforming TNBC treatment and offering patients a brighter future.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was successfully held in Barcelona, Spain. At this conference, a study led by Dr. Guodong He from Zhongshan Hospital, utilizing…

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production due to antibody-mediated mechanisms. Current first-line therapies for ITP include glucocorticoids and immunoglobulins, while second-line options often involve thrombopoietin receptor agonists (TPO-RAs), CD20 monoclonal antibodies, and splenectomy. The introduction of CD20 monoclonal antibody therapy over the past decade has transformed ITP treatment. However, heterogeneity in treatment response and duration leaves a subset of patients at risk of severe bleeding, reduced quality of life, and increased mortality. Following the success of CD20 antibodies, researchers have been exploring other potent therapeutic targets to address these unmet needs.